Fig. 2From: Tumor-related interleukins: old validated targets for new anti-cancer drug developmentSignaling pathways of IL-2. IL-2 activates JAK-STAT, PI3K and MAPK signaling pathways upon its engagement in the specific receptor complexes. The signaling pathway results in the activation and survival of Treg, CD8+ T cells and NK cellsBack to article page